Industries > Pharma > Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2020-2030

Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2020-2030

Forecasts by Product Type (Monoclonal Antibodies, Insulin, Cytokines, Vaccines, Blood Factors, Others), Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), Molecule (Small Molecule and Large Molecule), Container (Bottles, Ampoules, Vials, Bags, Pre-filled Syringes, Others) Plus Company Profiling of Major Players in the CMO of Sterile Injectable Drugs field

PUBLISHED: 01 May 2020
PAGES: 161
PRODUCT CODE: PHA0737
SUBMARKET: Contract Services

Clear
WOOCS 2.2.1
SKU: PHA0737 Categories: , Tags: , , ,

Our 161-page report provides 77 tables, 75 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing CMO of sterile injectable drugs market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments.

Discover sales predictions for the global market and submarkets
Along with revenue prediction for the overall world market, there are 4 segmentations of the CMO of sterile injectable drugs market, with forecasts for 5 product types, 6 applications, 2 molecules, 5 containers each forecasted at a global and regional level.

Global CMO of Sterile Injectable Drugs Market by Product Type
• Monoclonal antibodies
• Insulin
• Cytokines
• Vaccines
• Blood factors
• Others

Global CMO of Sterile Injectable Drugs Market by Application
• Cancer
• Diabetes
• Cardiovascular diseases
• CNS
• Infectious
• Others

Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2020-2030

Global CMO of Sterile Injectable Drugs Market by Molecule
• Large Molecule
• Small Molecule

Global CMO of Sterile Injectable Drugs Market by Container
• Bottles
• Ampoules
• Vials
• Prefilled syringes
• Bags

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:

• North America:
• US
• Canada

• Europe:
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe

• Asia-Pacific:
• Japan
• China
• India
• Rest of Asia-Pacific

• Latin America

• Middle East & Africa

Leading Companies covered in the report include:
• Jubilant Life Sciences Limited
• Boehringer Ingelheim
• Pfizer CentreOne
• Baxter Biopharma Solutions
• Recipharm AB
• Lonza
• Famar Health Care Services
• Patheon, Inc (Parent organization: Thermo Fischer company)
• Catalent, Inc
• Almac Group
• Evonik Industries AG
• Siegfried Holding AG
• Consort Medical, Plc.
• Aenova Group
• Grifols SA

The report also includes profiles and for some of the leading companies in the CMO of sterile injectable drugs market, with a focus on this segment of these companies’ operations:
• Famar Health Care Services
• Boehringer Ingelheim
• Baxter Biopharma Solutions
• Lonza
• Jubilant Life Sciences Limited

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., UK, Germany, Japan, India and China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth
Overall world revenue for CMO of sterile injectable drugs will surpass US$55.33 billion by 2030, our work calculates. We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the CMO of Sterile Injectable Drugs Market report helps you
In summary, our 160 pages report provides you with the following knowledge:
• Revenue forecasts to 2030 for 4 segmentations of the CMO of Sterile Injectable Drugs market, with forecasts for 5 product types, 6 applications, 2 molecules, 5 containers, each forecasted at a global and regional level–discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2030 for 5 regional and 11 key national markets – See forecasts for the CMO of Sterile Injectable Drugs market in North America, Latin America, Europe, Asia-Pacific and Middle East & Africa. Also forecasted is the market in the US, Canada, Germany, France, UK, Italy, Spain, China, India, and Japan.
• Drivers, Restraints, Challenges, Opportunities
• Porter’s Five Forces Analysis
• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the CMO of sterile injectable drugs market
• Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain study is for everybody needing commercial analyses for the CMO of Sterile Injectable Drugs market and leading companies. You will find data, trends and predictions.

Get our report today (CMO) of Sterile Injectable Drugs Market : Forecasts by Product Type (Monoclonal Antibodies, Insulin, Cytokines, Vaccines, Blood Factors, Others), Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), Molecule (Small Molecule and Large Molecule), Container (Bottles, Ampoules, Vials, Bags, Pre-filled Syringes, Others) Plus Company Profiling of Major Players.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2020-2030


Latest Pharma news

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

READ

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

READ

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

READ

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

READ

Categories

Category